Femasys Inc. (FEMY)
- Previous Close
1.0800 - Open
1.0700 - Bid 0.7776 x 200
- Ask 1.3600 x 200
- Day's Range
1.0600 - 1.1093 - 52 Week Range
0.8600 - 1.8000 - Volume
96,586 - Avg. Volume
416,658 - Market Cap (intraday)
29.964M - Beta (5Y Monthly) -2.52
- PE Ratio (TTM)
-- - EPS (TTM)
-0.8500 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
7.25
Femasys Inc., a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination solution; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; FemCath, a cornual balloon catheter for selective fallopian tube evaluation; and FemChec, a controlled contrast-generating device for fallopian tube diagnosis. It also develops FemBloc, a non-surgical permanent birth control solution. The company offers its products to reproductive endocrinologists, gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
www.femasys.comRecent News: FEMY
View MorePerformance Overview: FEMY
Trailing total returns as of 5/13/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: FEMY
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: FEMY
View MoreValuation Measures
Market Cap
29.96M
Enterprise Value
33.81M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
14.96
Price/Book (mrq)
15.01
Enterprise Value/Revenue
19.90
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.30%
Return on Equity (ttm)
-182.18%
Revenue (ttm)
1.63M
Net Income Avi to Common (ttm)
-18.82M
Diluted EPS (ttm)
-0.8500
Balance Sheet and Cash Flow
Total Cash (mrq)
3.45M
Total Debt/Equity (mrq)
322.96%
Levered Free Cash Flow (ttm)
-13.55M